000028 国药一致
2026/09 - 九个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入55,066,090-0.11%73,415,85874,378,49475,477,48573,443,137
减:营业总成本53,793,095-0.15%71,812,83073,017,47573,277,09771,309,688
    其中:营业成本49,499,1560.31%65,575,39166,129,20966,425,42664,516,926
               财务费用97,770-18.48%182,960239,424204,535189,514
               资产减值损失(16,141)299.36%(290,177)(994,532)(17,577)(71,588)
公允价值变动收益(7,058)-318.56%3,129(20,675)(15,161)28,871
投资收益126,327-23.47%217,607241,793237,029139,131
    其中:对联营企业和合营企业的投资收益164,730-27.81%315,684369,703315,446298,527
营业利润1,327,188-0.47%1,512,829573,4782,467,4252,306,069
利润总额1,316,990-0.05%1,509,020575,4692,473,2272,311,070
减:所得税费用301,0400.93%380,672338,466514,739539,332
净利润1,015,950-0.34%1,128,349237,0041,958,4871,771,738
减:非控股权益63,4601.90%(7,578)(405,490)359,231285,030
股东净利润952,490-0.48%1,135,927642,4931,599,2561,486,708

市场价值指针
每股收益 (元) *1.5600.00%2.0401.1502.8702.670
每股派息 (元) *----0.6160.3660.6800.800
每股净资产 (元) *31.393-5.20%33.43731.74731.29037.666
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容